Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia

Critical Care Medicine

Volumn 39, Issue 10, 2011, Pages 2211-2217

  Ramírez, Paula ^a   Ferrer, Miquel ^b   Martí, Verónica ^a,d   Reyes, Soledad ^a   Martínez, Raquel ^a   Menéndez, Rosario ^a   Ewig, Santiago ^c   Torres, Antoni ^b,d  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Department of Respiratory Medicine and Infectious Diseases ^*  (Germany)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

community acquired pneumonia guidelines; inflammatory biomarkers; intensive care unit admission; severe community acquired pneumonia; systemic inflammatory response

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DISEASE SEVERITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA SEVERITY INDEX; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 80052962577     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182257445     Document Type: Article

References (32)

1. Almirall J, Bolibar I, Vidal J, et al: Epidemiology of community-acquired pneumonia in adults: A population-based study. Eur Respir J 2000; 15:757-763 (Pubitemid 30196306)
2. Feagan BG, Marrie TJ, Lau CY, et al: Treatment and outcomes of community-acquired pneumonia at Canadian hospitals. CMAJ 2000; 162:1415-1420 (Pubitemid 30340307)
3. Guest JF, Morris A: Community-acquired pneumonia: The annual cost to the National Health Service in the UK. Eur Respir J 1997; 10:1530-1534 (Pubitemid 27311067)
4. Fine MJ, Stone RA, Singer DE, et al: Processes and outcomes of care for patients with community-acquired pneumonia: Results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999; 159:970-980 (Pubitemid 29222498)
5. Mandell LA, Wunderink RG, Anzueto A, et al: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-S72 (Pubitemid 46290553)
6. Liapikou A, Ferrer M, Polverino E, et al: Severe community-acquired pneumonia: Validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis 2009; 48:377-385
7. Phua J, See KC, Chan YH, et al: Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax 2009; 64:598-603
8. Brown SM, Jones BE, Jephson AR, et al: Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med 2009; 37: 3010-3016
9. Renaud B, Santin A, Coma E, et al: Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. Crit Care Med 2009; 37: 2867-2874
10. Restrepo MI, Mortensen EM, Rello J, et al: Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010; 137: 552-557
11. Tang BM, Eslick GD, Craig JC, et al: Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: Systematic review and meta-analysis. Lancet Infect Dis 2007; 7:210-217 (Pubitemid 46274517)
12. Schuetz P, Christ-Crain M, Muller B: Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 2007; 13:578-585 (Pubitemid 47357461)
13. Christ-Crain M, Opal SM: Clinical review: The role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010; 14:203
14. Kruger S, Ewig S, Marre R, et al: Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008; 31:349-355
15. Menendez R, Martinez R, Reyes S, et al: Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009; 64:587-591
16. Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873 (Pubitemid 38344143)
17. Fine MJ, Auble TE, Yealy DM, et al: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250 (Pubitemid 27044625)
18. Fischer JE, Bachmann LM, Jaeschke R: A readers' guide to the interpretation of diagnostic test properties: Clinical example of sepsis. Intensive Care Med 2003; 29: 1043-1051 (Pubitemid 36918544)
19. Povoa P: C-reactive protein: A valuable marker of sepsis. Intensive Care Med 2002; 28:235-243 (Pubitemid 34230643)
20. Almirall J, Bolibar I, Toran P, et al: Contribution of C-reactive protein to the diagnosis and assessment of severity of communityacquired pneumonia. Chest 2004; 125: 1335-1342 (Pubitemid 38501347)
21. Chirouze C, Schuhmacher H, Rabaud C, et al: Low serum procalcitonin level accurately predicts the absence of bacteremia in adult patients with acute fever. Clin Infect Dis 2002; 35:156-161 (Pubitemid 34753900)
22. Muller F, Christ-Crain M, Bregenzer T, et al: Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: A prospective cohort trial. Chest 2010; 138: 121-129
23. Kruger S, Papassotiriou J, Marre R, et al: Pro-atrial natriuretic peptide and provasopressin to predict severity and prognosis in community-acquired pneumonia: Results from the German competence network CAPNETZ. Intensive Care Med 2007; 33: 2069-2078 (Pubitemid 350164580)
24. Bruns AH, Oosterheert JJ, Hak E, et al: Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008; 32:726-732
25. Menendez R, Martinez R, Reyes S, et al: Stability in community-acquired pneumonia: One step forward with markers? Thorax 2009; 64:987-992
26. Christ-Crain M, Stolz D, Bingisser R, et al: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med 2006; 174:84-93 (Pubitemid 43955248)
27. Ramirez P, Ferrer M, Gimeno R, et al: Systemic inflammatory response and increased risk for ventilator-associated pneumonia: A preliminary study. Crit Care Med 2009; 37: 1691-1695
28. Yende S, D'Angelo G, Kellum JA, et al: Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008; 177:1242-1247 (Pubitemid 351860933)
29. Ioanas M, Ferrer M, Cavalcanti M, et al: Causes and predictors of non-response to treatment of the ICU-acquired pneumonia. Crit Care Med 2004; 32:938-945 (Pubitemid 38471513)
30. Cavalcanti M, Ferrer M, Ferrer R, et al: Risk and prognostic factors of ventilator-associated pneumonia in trauma patients. Crit Care Med 2006; 34:1067-1072
31. Martinez R, Menendez R, Reyes S, et al: Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. Eur Respir J 2011; 37:393-399
32. Martin-Loeches I, Lisboa T, Rodriguez A, et al: Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36:612-620